Vanguard Group Inc. Has $291.99 Million Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Vanguard Group Inc. grew its stake in Amedisys, Inc. (NASDAQ:AMED) by 0.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,216,120 shares of the health services provider’s stock after buying an additional 10,817 shares during the period. Vanguard Group Inc. owned approximately 0.10% of Amedisys worth $291,992,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. National Bank of Canada FI lifted its stake in Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after buying an additional 30,213 shares during the period. ABC Arbitrage SA bought a new stake in shares of Amedisys in the 4th quarter valued at about $2,522,000. Geode Capital Management LLC raised its position in shares of Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after acquiring an additional 7,071 shares during the period. Oddo BHF Asset Management Sas bought a new position in Amedisys during the 3rd quarter worth approximately $7,238,000. Finally, Empowered Funds LLC acquired a new position in Amedisys during the fourth quarter valued at approximately $318,000. 94.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Amedisys currently has an average rating of “Hold” and a consensus target price of $101.00.

Amedisys Trading Down 1.2 %

NASDAQ:AMED opened at $91.89 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The business’s 50-day simple moving average is $92.31 and its 200-day simple moving average is $92.32. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The stock has a market capitalization of $3.01 billion, a PE ratio of 36.46, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The company had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.